Clinical Trials on Hemoglobin C betegség

Total 2722 results

Medical University of Vienna

Completed

Interferon/Ribavirin-Free Sofosbuvir Based Treatment (AURIC) (AURIC)

Cirrhosis | Chronic Hepatitis C

Austria
TCM Biotech International Corp.

Withdrawn

The Effects of Adding TCM-700C on the Standard Combination Treatment for HCV Genotype 1 Patients(Phase III)

Chronic Hepatitis C

Taiwan, China
ANRS, Emerging Infectious Diseases

Completed

French Cohort of Therapeutic Failure and Resistances in Patients Treated With a Protease Inhibitor (Telaprevir or Boceprevir), Pegylated Interferon and Ribavirin (CUPIC)

Chronic Hepatitis C

France
Foundation for Liver Research
Janssen-Cilag B.V.

Completed

Effect of Teleprevir in Triple Therapy on Intrahepatic Immunological Mechanisms (ETIM)

Chronic Hepatitis C

Netherlands
Third Affiliated Hospital, Sun Yat-Sen University

Completed

A Randomized Trial of 24-Week Versus 48-Week Courses of Peginterferon Plus Ribavirin for HCV Genotype-6 Patients

Chronic Hepatitis C

China
Gilead Sciences

Completed

Sofosbuvir + Ribavirin for 12 or 16 Weeks in Treatment Experienced Subjects With Chronic Genotype 2 or 3 HCV Infection (FUSION) (FUSION)

Chronic Hepatitis C

United States, Canada, New Zealand, Puerto Rico
Valneva Austria GmbH

Completed

Virological Response Study of the HCV Vaccine IC41

Chronic Hepatitis C

Germany, Poland, Romania
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Boceprevir on HCV-specific T Cell Responses (Boce-Par)

Chronic Hepatitis C

Italy
Bristol-Myers Squibb

Completed

A Multiple Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States, Puerto Rico
Azienda Ospedaliera San Camillo Forlanini

Completed

HCV Genotype 1a Shows a Better Virological Response to Antiviral Therapy Than HCV Genotype 1b (genotype)

Chronic Hepatitis C

Italy
Májbetegekért Alapítvány
Hoffmann-La Roche

Unknown

Continuing Treatment With Pegasys and Copegus

Chronic Hepatitis C

Hungary
Phillip Coffin, MD, MIA
National Institute on Drug Abuse (NIDA)

Completed

Pilot Treatment as Prevention for HCV Among Persons Who Actively Inject Drugs (BYE-C)

Chronic Hepatitis C

United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability, Pharmacokinetics and Pharmacodynamics Study of HEC110114 Tablets in HCV-infected Subjects (HEC110114)

Chronic Hepatitis C

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

HCV

China
Sunshine Lake Pharma Co., Ltd.

Completed

The Tolerability and Pharmacokinetics Study of HEC110114 Tablets in Healthy Adult Subjects (HEC110114)

Chronic Hepatitis C

China
American Research Corporation
AbbVie

Completed

A Study to Investigate HCV Response Rates in Real World Patients: HEARTLAND Study (HEARTLAND)

Chronic Hepatitis C
Fundacion SEIMC-GESIDA

Withdrawn

A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A (C-RESCUE)

HCV

Spain
Merck Sharp & Dohme LLC

Terminated

Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Chronic Hepatitis C
Merck Sharp & Dohme LLC

Completed

A Drug-Drug Interaction Study Evaluating the Combination of IDX320 and IDX184 in Healthy Participants (MK-6844-002)

Chronic Hepatitis C
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Chronic Hepatitis C

United States, Argentina
Gilead Sciences

Completed

A Phase 1 Study to Evaluate the Pharmacokinetics of GS-5816 in Subjects With Normal Hepatic Function and Moderate or Severe Hepatic Impairment

Chronic Hepatitis C

United States, Puerto Rico
Vertex Pharmaceuticals Incorporated

Completed

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

Chronic Hepatitis C

United States
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-650032 in HCV Infected Subjects

Chronic Hepatitis C

United States
Arrow Therapeutics
DDS, Dundee; David Mutimer, Birmingham; Ed Gane, ACS New Zealand

Terminated

A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers (CP104)

Chronic Hepatitis C

New Zealand, United Kingdom
University of California, Irvine
University of California, Los Angeles; National Institute on Minority Health...

Completed

Development of a Community-based HCV Treatment Completion Intervention Among HCV Positive Homeless Adults

Hepatitis C Virus (HCV) Infection

United States
AbbVie

Completed

Efficacy Study Of Oral Glecaprevir/Pibrentasvir Tablet In Pediatric (12 Years and Older) And Adult Treatment-Naive Participants With Chronic Hepatitis C Genotypes 1 To 6 And Liver Cirrhosis (EASY)

Hepatitis C Virus (HCV)

Russian Federation
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate Chronic Hepatitis C Infection in Treatment Experienced Adults

Chronic Hepatitis C Infection
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Adults With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection (ENDURANCE-2)

Chronic Hepatitis C Virus (HCV) Infection
AbbVie

Completed

A Study to Evaluate the Safety and Antiviral Effect of Multiple Doses of ABT-493 and ABT-530 in Adults With Genotype 1 Hepatitis C Virus (HCV)

Chronic Hepatitis C | Hepatitis C Virus | Compensated Cirrhosis
AbbVie (prior sponsor, Abbott)

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Multiple Doses of ABT-333 Alone and in Combination With Pegylated Interferon (pegIFN) and Ribavirin (RBV) in Subjects With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C Virus Infection

United States, Puerto Rico
AbbVie

Completed

A Study to Evaluate the Efficacy and Safety of Three Experimental Drugs Compared With Telaprevir (a Licensed Product) in People With Hepatitis C Virus Infection Who Have Not Had Treatment Before (MALACHITE 1)

Chronic Hepatitis C Infection
VA Office of Research and Development
GlaxoSmithKline

Completed

Herpes Simplex Type 1 Suppression in Hepatitis C (HSV1/HCV)

Chronic Hepatitis C Infection

United States
Saint Michael's Medical Center

Completed

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

HIV Infection | Hepatitis C Infection

United States
University Hospital, Strasbourg, France

Unknown

Clinical Investigation of Erlotinib as an HCV Entry Inhibitor

Chronic Hepatitis C Infection | HCV Genotype 1b

France
Prof. Dr. Alice Schmidt

Unknown

Hepatitis C in Renal Transplant Recipients

Renal Transplantation | Chronic Hepatitis C-virus Infection

Austria
Beth Israel Medical Center

Terminated

Assessing the Efficacy and Safety of Rosiglitazone Added to Standard Therapy for Hepatitis C Genotype 1 With Fatty Liver

Fatty Liver | Chronic Hepatitis C Infection

United States
Sunshine Lake Pharma Co., Ltd.

Completed

Drug-drug Interaction Study Between HEC74647PA Capsule and HEC110114 Tablets in Healthy Subjects

Chronic Hepatitis C

China
Hoffmann-La Roche

Completed

Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection

HCV

Puerto Rico, United States
Sandoz

Completed

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions

Chronic Hepatitis C
Sandoz

Completed

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Fasting Conditions

Chronic Hepatitis C
Mitsubishi Tanabe Pharma Corporation

Completed

Clinical Pharmacology Study of MP-424

Chronic Hepatitis C

Korea, Republic of
Debiopharm International SA

Completed

A Study of Debio 025 in Combination With PegIFN Alpha-2a and Ribavirin in Chronic HCV Patients Non-responders to Standard Treatment

Chronic Hepatitis C

United States
Gilead Sciences

Completed

Open-Label Study of Sofusbuvir+Ribavirin With or Without Peginterferon Alfa-2a in Subjects With Chronic HCV Infection Who Participated in Prior Gilead HCV Studies

Chronic Hepatitis C

United States, Germany, Australia, United Kingdom, France, Netherlands, Canada, New Zealand, Italy, Poland, Austria, Estonia, Spain, Sweden, Puerto Rico, Czech Republic
Foundation for Liver Research

Completed

Effect of ASV and DCV Therapy on the Quality of Immune Status in Chronic HCV Patients (ImmunoDual)

Chronic Hepatitis C

Netherlands
Bristol-Myers Squibb

Completed

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

Chronic Hepatitis C

United States, Canada
St Vincent's Hospital Melbourne
Merck Sharp & Dohme LLC

Unknown

A Pilot Study of Boceprevir for the Treatment of Genotype 6 HCV (HCV-6)

Chronic Hepatitis C

Australia
Pfizer

Completed

Drug Interaction Study Of Filibuvir With Methadone Among Subjects On Chronic Methadone Maintenance

Chronic Hepatitis C

United States
Erasme University Hospital

Completed

sgp130 in Chronic Human Liver Disease

Chronic Hepatitis C Virus Infection | Alcoholic Liver Disease

Belgium
Johns Hopkins University
AbbVie

Recruiting

Rapid HCV Treatment Access for Persons Who Use Drugs (RAPID-HCV)

Hepatitis C Virus Infection, Response to Therapy of

United States, Canada
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Chronic Hepatitis C

3

Subscribe